Indian Gooseberry (Expanded) for Cholesterol Management

Research suggests that Indian gooseberry (amla) supplementation is associated with improvements across multiple lipid markers, including reductions in LDL cholesterol, total cholesterol, triglycerides, and VLDL, alongside increases in HDL cholesterol. The evidence base includes two meta-analyses of randomized controlled trials, several individual RCTs, clinical comparisons with established lipid-lowering medications, mechanistic studies pointing to HMG-CoA reductase inhibition as a possible pathway, and animal research suggesting involvement of gut microbiome and liver metabolism. Studies indicate the overall direction of findings is consistently supportive, and one meta-analysis pooling data from nine trials across 535 adults reported statistically significant benefits on key cardiovascular risk markers. However, that same meta-analysis cautioned that the number of trials remains small, study designs vary considerably, and prediction intervals for some outcomes were wide enough to include zero effect, meaning confidence in the magnitude of benefit for any given individual is still limited and more rigorous, standardized trials are needed before firm conclusions can be drawn.